Procaps Issues Shareholder Letter

Core Viewpoint - Procaps Group is navigating significant operational and macroeconomic challenges while focusing on internal investigations and strategic priorities to ensure long-term growth and profitability [1][5][14]. Current Business State - The company is undergoing an internal investigation related to historical accounting practices, which has delayed the filing of its audited financial statements for 2023 [4][11]. - Recent legal actions by Hoche Partners were dismissed by the Luxembourg Court, reinforcing Procaps' position [6][7][8]. - The company has entered into forbearance agreements with lenders covering over $190 million of debt, providing temporary financial relief of approximately $20 million for August, September, and October [9][10]. Financial Performance - For the six months ended June 30, 2024, net revenues were approximately $190 million, a 2% decline from $194 million in the same period of 2023, primarily due to lower sales volumes and destocking efforts [21]. - Adjusted EBITDA for 1H24 is estimated to be between $8 million and $10 million, a significant decline from $29 million in 1H23, impacted by destocking and economic challenges in Ecuador [22][23]. - Gross debt as of June 30, 2024, stood at approximately $285 million, reflecting a slight increase from $282 million a year earlier [25]. Strategic Priorities - The company aims to resolve the internal investigation and release audited financials as a top priority [27]. - Plans to reorganize internal operations are underway to enhance efficiency and adapt to market changes [27]. - Evaluation of non-core assets is being conducted to simplify the portfolio and strengthen the financial position, with potential sales of underperforming businesses expected within 12 to 18 months [29]. Market Context - The Latin American pharmaceutical market has experienced a slowdown, with market growth decreasing from 6.6% in June 2023 to 2.2% in June 2024 [16]. - Despite these challenges, Procaps achieved a growth rate of 5.1% YTD June 2024, outperforming the market and ranking as the second fastest-growing company in its sector [17].